This event has ended. Recordings of the event are available to watch below.
On World Bronchiectasis Day (1 July), we wanted to raise awareness about bronchiectasis around the world. This webinar was aimed at people with bronchiectasis and their family members/caregivers. However, anyone who would like to understand more about this condition was welcome to join.
The session focussed on current and future treatments for bronchiectasis. Questions were submitted about this topic to be answered by our panel of bronchiectasis experts.
The experts answered as many of these questions as they could during the 1-hour webinar. Attendees also wrote questions in the chat during the webinar and had them answered by our experts.
Stefano Aliberti is Professor of Respiratory Medicine at the University of Milan, and consultant at the Respiratory Department and Adult Cystic Fibrosis Center at the Policlinico Hospital in Milan, Italy. He is the director of the Bronchiectasis, Non-Tuberculous Mycobacteria and Primary Ciliary Dyskinesia programs of the Policlinico Hospital.
His major clinical and research interests are in both acute and chronic respiratory infections. He has extensive experience in epidemiological and clinical research in pneumonia.
He has been heavily involved in bronchiectasis and non-tuberculous mycobacteria. He founded the European Bronchiectasis Registry (EMBARC). Prof. Aliberti has published up to 200 peer-reviewed articles mainly on respiratory infections and he was part of international task forces to produce guidelines on bronchiectasis and severe pneumonia, as well as statements on tuberculosis.
Michal Shteinberg received her MD and a PhD in biochemistry from the Technion-Israel institute of technology. She trained in internal medicine and pulmonology, with a Fellowship in bronchiectasis and adult CF.
Prof. Shteinberg is Head of Bronchiectasis and Adult Cystic Fibrosis Unit, Carmel Medical Center, and the Technion - Israel Institute of Technology, the B. Rappaport Faculty of Medicine, Haifa, Israel.
She is a Clinical Associate Professor in the Faculty of medicine at the Technion, Israel Institute of Technology, and a member of the executive committee of the Israeli Society for Tuberculosis and mycobacterial diseases.
Her main research interests are bronchiectasis and its overlap with other airway diseases, mainly rhinosinusitis, and connective tissue diseases, as well as adult CF.
Prof. Shteinberg is a member of EMBARC management and heading Patient Activities Work package.
Danielle is a Physiotherapist at Carmel Hospital Haifa Israel. She is Inpatient Pulmonary Rehabilitation Coordinator and part of the Respiratory Physiotherapist Clalit Home Treatment Team.
Danielle has a specialist interest in treatment and management of bronchiectasis within the acute and chronic settings.
Professor James Chalmers is the British Lung Foundation Chair of Respiratory Research at the University of Dundee, UK, and a consultant respiratory physician.
He is an expert in lung infections and has been involved in a number of projects during the COVID-19 pandemic, including leading the ERS Guidelines Task Force for COVID-19 and being chief investigator for several trials of new COVID-19 treatments.
He works closely with ELF to involve patients in respiratory infection research through projects such as EMBARC, and is an advocate for involving patients in guidelines, clinical research, and clinical trials.
This event was co-developed with EMBARC, a pan-European network committed to promoting clinical research and education in bronchiectasis and the ELF Bronchiectasis Patient Advisory Group.
This webinar took place on World Bronchiectasis Day on 1 July. 
Find out more about how global partners are raising awareness of bronchiectasis and for other upcoming events.
ELF does not charge for its events and materials. We want to make sure they are available to anybody who wishes to join or use them. To ensure we can keep doing this we ask that those who can afford to pay to make a donation.
We are grateful to everyone who supports us in this way and helps lung health patients to understand more about their condition and have their voices heard.
